Locteron Showing Promise for Hepatitis C | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Encouraging HCV Results Issued by Roche

Back to News Homepage
Next

Eliminating HCV in Previous Non-Responders

Locteron Showing Promise for Hepatitis C

The Editors at Hepatitis Central
November 8, 2007

Print this page

OctoPlus has reported positive results from a Phase IIa trial for the Hepatitis C drug Locteron. Thus far, Locteron is encouraging due to its convenient dosing schedule, tolerability and Hepatitis C anti-viral activity.

OctoPlus says hepatitis C drug effective in study

Tue Nov 6, 2007

AMSTERDAM (Reuters) – Dutch biotechnology firm OctoPlus said on Tuesday European safety and efficacy Phase IIa studies have shown an antiviral effect for its chronic hepatitis C drug Locteron.

“A statistically significant dose response was observed in the study,” the company said in a statement, adding that the drug was tolerated at all doses.

The company, which has four other products in pre-clinical and clinical development, said approximately 90 percent of adverse events were rated as mild.

OctoPlus is co-developing Locteron with its partner Biolex Therapeutics, which plans to commence a European safety and efficacy Phase IIb trial of the drug in mid-2008.

With Locteron, OctoPlus is aiming to develop a treatment for patients with chronic hepatitis C, with fewer side effects and a more convenient dosing schedule compared with current therapies.

(Reporting by Harro ten Wolde)

No Comments - be the first!
Share
Share
Previous

Encouraging HCV Results Issued by Roche

Back to News Homepage
Next

Eliminating HCV in Previous Non-Responders

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.